MyMeds&Me Announce Collaboration with Oracle Health Sciences
London, UK, 25 March, 2015: MyMeds&Me, a leading SaaS provider of web-based adverse event and product quality capture solutions for life sciences, today announced their collaboration with Oracle Health Sciences to provide the Reportum® solution to Oracle Argus safety customers.
This collaboration allows access to the innovative Reportum® solution providing a standardised method of capturing complete Adverse Event data at source, from all reporter types. The Reportum® solution provides simple, web-based, user-friendly safety data capture at initial reporter interaction and supports direct reporting by consumers - streamlining what is often a paper-based activity that generates duplicate data entry processes, call centres - often dealing with high volumes of contacts with varying levels of experience and healthcare professionals.
For Oracle customers, the Oracle Argus pharmacovigilance platform will provide the hub for all safety and product quality data captured via the Reportum® solution. They will be able to review, manage, analyse and report all safety and product quality data consistently, irrespective of reporting route.
This combined solution will enable life science companies with Adverse Event obligations to: o Increase pharmacovigilance efficiency and reduce cost
o Deliver complete, cleaner data to regulators, faster
o Improve understanding of benefit risk profiles for pharmaceutical products
Dr. Andrew Rut, CEO at MyMeds&Me comments, “The recent ISMP report1 highlighted the scale of the issue of non-complete AE data submitted to the FDA. We believe the collaboration with Oracle Health Sciences delivers innovation to Oracle Argus Safety customers who will benefit from rapid access to complete and cleaner safety data, irrespective of reporter route, by implementing the Reportum® solution”.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
